@prefix this: <http://www.tkuhn.ch/bel2nanopub/RAYOtOiu0iABg1nvoxPR0hcBwLx915vRArmMm5eYH20BA> .
@prefix sub: <http://www.tkuhn.ch/bel2nanopub/RAYOtOiu0iABg1nvoxPR0hcBwLx915vRArmMm5eYH20BA#> .
@prefix beldoc: <http://resource.belframework.org/belframework/20131211/knowledge/large_corpus.bel> .
@prefix rdfs: <http://www.w3.org/2000/01/rdf-schema#> .
@prefix rdf: <http://www.w3.org/1999/02/22-rdf-syntax-ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .
@prefix dct: <http://purl.org/dc/terms/> .
@prefix dce: <http://purl.org/dc/elements/1.1/> .
@prefix pav: <http://purl.org/pav/> .
@prefix np: <http://www.nanopub.org/nschema#> .
@prefix belv: <http://www.selventa.com/vocabulary/> .
@prefix prov: <http://www.w3.org/ns/prov#> .
@prefix go: <http://amigo.geneontology.org/amigo/term/GO:> .
@prefix Protein: <http://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI_36080> .
@prefix hgnc: <http://www.genenames.org/cgi-bin/gene_symbol_report?hgnc_id=> .
@prefix geneProductOf: <http://purl.obolibrary.org/obo/RO_0002204> .
@prefix hasAgent: <http://semanticscience.org/resource/SIO_000139> .
@prefix mesh: <http://purl.bioontology.org/ontology/MSH/> .
@prefix obo: <http://purl.obolibrary.org/obo/> .
@prefix occursIn: <http://purl.obolibrary.org/obo/BFO_0000066> .
@prefix do: <http://disease-ontology.org/term/DOID:> .
@prefix species: <http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?id=> .
@prefix pubmed: <http://www.ncbi.nlm.nih.gov/pubmed/> .
@prefix orcid: <http://orcid.org/> .

sub:Head {
  this: np:hasAssertion sub:assertion;
    np:hasProvenance sub:provenance;
    np:hasPublicationInfo sub:pubinfo;
    a np:Nanopublication .
}

sub:assertion {
  sub:_1 hasAgent: sub:_2;
    a go:0016301 .
  
  sub:_2 geneProductOf: hgnc:391;
    a Protein: .
  
  sub:_3 occursIn: do:162, obo:CLO_0001686, species:9606;
    rdf:object mesh:D017209;
    rdf:predicate belv:decreases;
    rdf:subject sub:_1;
    a rdf:Statement .
  
  sub:assertion rdfs:label "kin(p(HGNC:AKT1)) -| bp(MESHPP:Apoptosis)" .
}

sub:provenance {
  beldoc: dce:description "Approximately 61,000 statements.";
    dce:rights "Copyright (c) 2011-2012, Selventa. All rights reserved.";
    dce:title "BEL Framework Large Corpus Document";
    pav:authoredBy sub:_5;
    pav:version "20131211" .
  
  sub:_4 prov:value "COX-2 inhibitors can also activate prosurvival pathways. The PI3K/Akt pathway is a survival pathway, frequently activated in cancer cells [49]. PI3K produces PIP3 (phosphatidylinositol 3,4,5 triphosphate) that activates PDK1 (pyruvate deshydrogenase kinase). This protein phosphorylates and activates PKB (protein kinase B), which, in turn, is responsible for the phosphorylation of several targets playing a modulator function in apoptosis. An anti-cancer effect of celecoxib due to the inhibition of Akt signaling [111] was observed in a gastric cancer model. ";
    prov:wasQuotedFrom pubmed:20339581 .
  
  sub:_5 rdfs:label "Selventa" .
  
  sub:assertion prov:hadPrimarySource pubmed:20339581;
    prov:wasDerivedFrom beldoc:, sub:_4 .
}

sub:pubinfo {
  this: dct:created "2014-07-03T14:33:38.731+02:00"^^xsd:dateTime;
    pav:createdBy orcid:0000-0001-6818-334X, orcid:0000-0002-1267-0234 .
}